Polymyalgia rheumatica and giant cell arteritis following COVID-19 vaccination: Results from a nationwide survey
Description
We conducted a national in-depth analysis including pharmacovigilance reports and clinical study to assess the reporting rate (RR) and to determine the clinical profile of polymyalgia rheumatica (PMR) and giant cell arteritis (GCA) in COVID-19
